Mr. Hasija joined Milestone as Chief Financial Officer in September 2019. Prior to Milestone Pharmaceuticals, Mr. Hasija served as Chief Financial Officer and Chief Business Officer at Fulcrum Therapeutics, a publicly traded, clinical-stage biopharmaceutical company focused on developing therapies for genetically defined rare diseases.
Mr. Oliveto has served as Milestone’s President and Chief Executive Officer since March 2017 and as a member of Milestone’s board of directors since July 2017. Prior to Milestone Pharmaceuticals, Mr. Oliveto was President, CEO and a Director of Chelsea Therapeutics International, Ltd.